Chen P, et al. - Researchers performed a meta-analysis evaluating the clinical efficacy and safety of osimertinib in the treatment for non-small-cell lung cancer (NSCLC). They searched PubMed, EMBASE, Cochrane Library, and China National Knowledge Infrastructure using “osimertinib” as a keyword combined with “non-small-cell lung cancer” and “randomized controlled trial” as medical subject headings and identified 10 studies meeting their criteria, with a total of 3,260 participants. Findings suggest osimertinib as effective in demonstrating a significant improvement in the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) with tolerable adverse effects for NSCLC patients. However, because of some clear limitations (heterogeneity and publication bias), they recommend interpreting the results with caution.